BRPI0415420A - igg3 úteis para estimular a fagocitose - Google Patents

igg3 úteis para estimular a fagocitose

Info

Publication number
BRPI0415420A
BRPI0415420A BRPI0415420-7A BRPI0415420A BRPI0415420A BR PI0415420 A BRPI0415420 A BR PI0415420A BR PI0415420 A BRPI0415420 A BR PI0415420A BR PI0415420 A BRPI0415420 A BR PI0415420A
Authority
BR
Brazil
Prior art keywords
igg3
useful
phagocytosis
stimulating phagocytosis
stimulating
Prior art date
Application number
BRPI0415420-7A
Other languages
English (en)
Inventor
Christophe De Romeuf
Sylvie Jorieux
Dominique Bourel
Philippe Klein
Nicolas Bihoreau
Original Assignee
Lab Francais Du Fractionnement
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lab Francais Du Fractionnement filed Critical Lab Francais Du Fractionnement
Publication of BRPI0415420A publication Critical patent/BRPI0415420A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

"IgG3 úTEIS PARA ESTIMULAR A FAGOCITOSE". A presente invenção refere-se a anticorpos monoclonais quiméricos, humanizados ou humanos de classe IgG3 produzidos em uma linhagem celular de mieloma de rato, notadamente a linhagem YB2/0. Esses anticorpos apresentam uma forte atividade em fagocitose e podem ser administrados para tratar os cânceres e as infecções.
BRPI0415420-7A 2003-10-16 2004-10-18 igg3 úteis para estimular a fagocitose BRPI0415420A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0312087A FR2861078B1 (fr) 2003-10-16 2003-10-16 NOUVELLES IgG3 UTILES POUR STIMULER LA PHAGOCYTOSE
PCT/FR2004/002657 WO2005037866A2 (fr) 2003-10-16 2004-10-18 Igg3 anti rhesus-d dans la lignee yb2/0 ayant une forte activite en phagocytose

Publications (1)

Publication Number Publication Date
BRPI0415420A true BRPI0415420A (pt) 2006-12-05

Family

ID=34385205

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415420-7A BRPI0415420A (pt) 2003-10-16 2004-10-18 igg3 úteis para estimular a fagocitose

Country Status (9)

Country Link
US (1) US20070218052A1 (pt)
EP (1) EP1675616A2 (pt)
JP (1) JP2007533639A (pt)
AU (1) AU2004281220A1 (pt)
BR (1) BRPI0415420A (pt)
CA (1) CA2542508A1 (pt)
FR (1) FR2861078B1 (pt)
IL (1) IL174949A0 (pt)
WO (1) WO2005037866A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005053742A1 (ja) * 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
FR2957598B1 (fr) 2010-03-17 2015-12-04 Lfb Biotechnologies Nouveau peptide signal, et son utilisation pour la production de proteines recombinantes
FR3003171B1 (fr) * 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496548A (en) * 1987-09-18 1996-03-05 National Blood Authority Human anti-RH(D) monoclonal antibodies, cell lines and methods of use of antibodies in immunoassays
FI940811L (fi) * 1992-06-26 1994-02-21 Aetsrn Ihmisen monoklonaalisia anti-Rhesus(D) -vasta-aineita ja niitä tuottavat solulinjat
DE10001372A1 (de) * 2000-01-14 2001-08-02 Deutsches Krebsforsch Anti-CD3-Einzelketten-Antikörper mit humanem Cmu3- und Cmu4- Domänen
FR2807767B1 (fr) * 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
US7605235B2 (en) * 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions

Also Published As

Publication number Publication date
AU2004281220A1 (en) 2005-04-28
FR2861078A1 (fr) 2005-04-22
WO2005037866A3 (fr) 2005-07-21
US20070218052A1 (en) 2007-09-20
JP2007533639A (ja) 2007-11-22
WO2005037866A2 (fr) 2005-04-28
EP1675616A2 (fr) 2006-07-05
WO2005037866A8 (fr) 2006-06-01
CA2542508A1 (fr) 2005-04-28
IL174949A0 (en) 2006-08-20
FR2861078B1 (fr) 2007-09-21

Similar Documents

Publication Publication Date Title
MY154009A (en) Anti-alpha v beta 6 antibodies
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
EA200700083A1 (ru) Антитела, направленные против бета-амилоидного пептида, и способы их применения
ATE482719T1 (de) Behandlungsverfahren unter verwendung von anti- cd22-antikörpern
MY144612A (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
ATE438411T1 (de) Dosierung für die behandlung mit anti erbb2- antikörpern
WO2007008712A3 (en) Anti-alpha v beta 6 antibodies and uses thereof
EP1470146B8 (en) Antibodies against the muc18 antigen
DE60033530D1 (de) Humane antikörper gegen ctla-4 und deren verwendungen
CY1118063T1 (el) ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ΑΝΘΡΩΠ1ΝΗΣ IgE ΥΨΗΛΗΣ ΣΥΓΓΕΝΕΙΑΣ
ATE476992T1 (de) Neutralisierbares epitop von hgf und an dieses bindende neutralisierender antikörper
EA201070596A1 (ru) Гуманизированные антитела против tl1a
TR200102733T2 (tr) IL-18 kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri
WO2003057006A3 (en) Use of antibodies against the muc18 antigen
WO2003057837A3 (en) Methods for using anti-muc18 antibodies
ATE384744T1 (de) Menschliche antikörper gegen her2/neu
NZ595235A (en) Compositions and methods for increasing muscle growth
MX2009005743A (es) Nuevos anticuerpos monoclonales de globulomero anti-ab selectivos del conformero ab.
DE602004029252D1 (de) Aglycosyl-anti-cd154 (cd40-ligand) antikörper und deren verwendungen
CY1109817T1 (el) Ολιγο-βητα-(1,3)-γλυκανη και μονοκλωνικα αντισωματα εναντιον καρκινου
WO2004108766A3 (en) Anti-hgf-r antibodies and their use
BRPI0413119A (pt) uso de anticorpos com adcc otimizada para tratar pacientes debilitados
WO2004069183A3 (en) Immune regulation based on the targeting of early activation molecules
WO2005080428A3 (en) Anti-epcam immunoglobulins
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.